August 27, 2003
Speeding Up the Process
"By studying different vaccine design strategies at once, rather than one at a time, South Africa will help to reduce the time needed to identify which is the most effective," IAVI President and CEO Dr. Seth Berkley said, adding, "In the search for an AIDS vaccine, speed is of the essence." The two vaccines are some of more than 20 that are currently in human clinical trials or waiting to enter human trials, according to the Star (Star, 8/26). IAVI's HIVA.MVA vaccine candidate is based on HIV-1 subtype A, which is common in east Africa, and AlphaVax's AVX101 is based on HIV-1 subtype C, which is most common in South Africa. "Ideally, a single AIDS vaccine will be highly effective against all subtypes of HIV," Dr. Wayne Koff, IAVI's senior vice president for research and development, said. He added, "Preliminary indications are that both of the vaccine candidates currently approved for testing in South Africa hold promise for meeting this goal, but only human trials will tell us for sure" (SAPA/Business Day, 8/26). Dr. Tim Tucker, executive director of the South African AIDS Vaccine Initiative, which coordinates AIDS vaccine research in South Africa, said, "What is happening in South Africa should be a model for the world. Local scientists are working in collaboration with international partners to streamline the process of discovering a preventive AIDS vaccine" (IAVI release, 8/25).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2003 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.